Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial

Journal of Hypertension

Volumn 34, Issue 8, 2016, Pages 1639-1647

  Mathiassen, Ole N ^a   Vase, Henrik ^a   Bech, Jesper N ^b   Christensen, Kent L ^a   Buus, Niels H ^a   Schroeder, Anne P ^c   Lederballe, Ole ^c   Rickers, Hans ^d   Kampmann, Ulla ^a   Poulsen, Per L ^a   Hansen, Klavs W ^e   Bøtker, Hans E ^a   Peters, Christian D ^a   Engholm, Morten ^a   Bertelsen, Jannik B ^a   Lassen, Jens F ^a   Langfeldt, Sten ^a   Andersen, Gratien ^a   Pedersen, Erling B ^b   Kaltoft, Anne ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HOLSTEBRO HOSPITAL   (Denmark)

^c VIBORG HOSPITAL   (Denmark)

^d RANDERS REGIONAL HOSPITAL   (Denmark)

^e SILKEBORG REGIONAL HOSPITAL   (Denmark)

Author keywords

ambulatory blood pressure measurement; randomized controlled trial; renal denervation; SHAM procedure; treatment resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ABLATION CATHETER; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR CATHETER; CONTROLLED STUDY; CONVULSION; CORONARY ANGIOGRAPHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; EFFICACY PARAMETERS; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEMATOMA; HIGH VOLUME HOSPITAL; HUMAN; KIDNEY ANGIOGRAPHY; KIDNEY DENERVATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANT ESSENTIAL HYPERTENSION; RESISTANT HYPERTENSION; THORAX PAIN; UNSTABLE ANGINA PECTORIS; AGED; BLOOD PRESSURE; CATHETER ABLATION; CORONARY VASOSPASM; HYPERTENSION; INNERVATION; KIDNEY; MIDDLE AGED; PROCEDURES; SYMPATHECTOMY;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETER ABLATION; CORONARY VASOSPASM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; SYMPATHECTOMY;

EID: 84970024022     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000977     Document Type: Article

References (27)

1. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383:622-629.
2. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. 36 Month Results From The Symplicity Htn-2 Randomized Clinical trial. Eur Heart J 2014; 35:1752-1759
3. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015; 65:766-774.
4. Sarafidis P, Bakris G. Resistant hypertension. An overview of evaluation and treatment. J Am Coll Cardiol 2008; 52:1749-1757.
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 117:510-526.
6. Persell SD Prevalence of Resistant Hypertension in the United States 2003-2008. Hypertension 2011 57 1076-1076.
7. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
8. Bhatt DL, Kandzari DE, O?Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393-1401.
9. Kjeldsen SE, Fadl Elmula FE, Persu A, Jin Y, Staessen JA Renal sympathetic denervation in the aftermath of Symplicity HTN-3. Blood Press 2014; 23:256-261
10. Esler M. Renal denervation for treatment of drug-resistant hypertension. Trends Cardiovasc Med 2015; 25:107-115.
11. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
13. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014; 63:991-999.
14. Vase H, Mathiassen ON, Kaltoft A, Pedersen EB, Christensen KL, Buus NH, et al. Catheter-based renal denervation for treatment of resistant in hypertension. Dan Med J 2012; 59:A4439.
15. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
16. Pedersen EB, Eiskjaer H, Madsen B, Danielsen H, Egeblad M, Nielsen CB. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. Nephrol Dial Transplant 1993; 8:1064-1070.
17. http://www.whocc.no/ddd/definition-And-general-considera/.
18. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427.
19. Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J 2011; 19:319-323.
20. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197.
21. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, et al. Anatomic assessment of sympathetic peri-Arterial renal nerves in man. J Am Coll Cardiol 2014; 64:635-643.
22. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36:219-227.
23. Patel HC, Hayward C, Ozdemir BA, Rosen SD, Krum H, Lyon AR, et al. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. Hypertension 2015; 65:401-406.
24. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:1957-1965.
25. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015; 65:1202-1208.
26. Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015; 65:193-199.
27. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31:766-774.